Autres langues Kinnate Biopharma Inc.

Actions

KNTE

US49705R1059

Temps Différé Nasdaq Autres places de cotation 22:00:00 02/04/2024			Varia. 5j.	Varia. 1 janv.
2,65 ^USD	-0,38 %		0,00 %	+11,81 %

03/04	Kinnate Biopharma Inc. annonce la démission de membres de son conseil d'administration	CI
03/04	XOMA Corporation (NasdaqGM:XOMA) a conclu l'acquisition de Kinnate Biopharma Inc. (NasdaqGS:KNTE).	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Kinnate Biopharma Inc. Announces Board Resignations	03/04
XOMA Corporation Announces Closing of Tender Offer	03/04
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index	03/04
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	03/04
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from S&P TMI Index	03/04
North American Morning Briefing : Stocks Seen -2-	02/04
Kinnate Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
North American Morning Briefing : Markets Steady -2-	26/03
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	19/03
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE	13/03
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories	04/03
Kinnate Biopharma Sells Cancer Treatment Assets to Pierre Fabre Laboratories	01/03
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories	01/03
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories	01/03
KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE	19/02
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	19/02
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.	16/02
Sector Update: Health Care Stocks Advance Friday Afternoon	16/02
XOMA Agrees to Acquire Kinnate Biopharma	16/02
KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders	16/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Kinnate Biopharma Inc.

Actions

KNTE

US49705R1059

Autres langues

Filtres